177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with
177Lu-DOTATOC results in fewer adverse events than standard PRRT. Subjects will be randomized
to either receive personalized or standard PRRT. Personalized PRRT will be determined based
on dosimetry calculations after the first cycle. In addition comparisons, will be made with
progression-free survival, serial CT imaging, ctDNA, and quality of life questionnaires.
Subjects will be followed for 5 years or until they have progression and are switched to
another systemic treatment (not including treatment with somatostatin analogues).